Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)

PHASE4RecruitingINTERVENTIONAL
Enrollment

1,220

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Atrial FibrillationLeft Atrial Appendage AbsentAnticoagulant Adverse Reaction
Interventions
DRUG

OAC will be discontinued for the duration of the trial

Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban

Trial Locations (6)

Unknown

NOT_YET_RECRUITING

Rigshospitalet, Copenhagen

RECRUITING

Gentofte Hospital, Gentofte Municipality

NOT_YET_RECRUITING

Regionshospital Gødstrup, Herning

NOT_YET_RECRUITING

Aalborg university hospital, Aalborg

RECRUITING

Århus Universitetshospital, Aarhus

RECRUITING

Odense University Hospital, Odense

Sponsors
All Listed Sponsors
collaborator

Rigshospitalet, Denmark

OTHER

collaborator

Gødstrup Hospital

OTHER

collaborator

Aarhus University Hospital

OTHER

collaborator

Aalborg University Hospital

OTHER

collaborator

Population Health Research Institute

OTHER

collaborator

Region of Southern Denmark

OTHER

lead

Odense University Hospital

OTHER

NCT06401616 - Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC) | Biotech Hunter | Biotech Hunter